Icelandic Biotech Alvotech Gets the Green Light

by | Jun 7, 2022

3 merger votes today. The usual extensions. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

OACB / Alvotech Approved

Oaktree Acquisition Corp. II (OACB) approves merger with Icelandic biotech Alvotech Holdings S.A. (ALVO). Expected close on or about June 15, 2022.

DWIN Extends

Delwinds Insurance Acquisition Corp. (DWIN) 9M shares redeemed (~45%). SPAC adds $0.035 / month deposit until 9/15. To merge with FOXO Technologies. We chatted with FOXO CEO Jon Sabes back in April. See the podcast here.

GACQ Extends

Global Consumer Acquisition Corp. (GACQ) gets first of two extensions to 9/11/2022. SPAC adds $0.10 to trust, ~$10.15 NAV.

VCKA Extends

Vickers Vantage Corp. I (VCKA) files for another extension to August (vote 6/30), and up to 5 more months without a vote to January. Adds $0.033 / month. DA with Scilex.

Symbotic Trades Tomorrow

AI-enabled robotics specialist Symbotic deSPACs tomorrow as SYM.

Elsewhere in SPACs

Other merger votes today

  • Globis Acquisition Corp. GLAQ / Forafric Agro Holdings
  • Dynamics Special Purpose Corp. DYNS / Senti Bio

Boardroom Alpha SPAC Market Review for May

Time is running out as SPACs scramble to finance deals at almost any cost. Expect more deSPAC duds as sponsors push low-quality companies at onerous valuations — for the simple purpose of protecting at-risk capital. Full report here.

SPAC Calendar

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.